Sequenom Posts 28 Percent Increase in Q4 Revenues as SEC Wraps up Investigation | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market on Tuesday that total revenues for the fourth quarter rose 28 percent on higher system and consumables sales.

Sequenom Chairman and CEO Harry Hixson also said that a nearly two-year old investigation by the US Securities and Exchange Commission may be coming to an end and the agency may bring civil injunction action against the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.